if new like myself just saw this:
Fly On The Wall
March 25, 2013
07:15 EDT SRPT Sarepta should appreciate regardless of accelerated approval, Leerink reiterates its belief that shares of Sarepta should move higher whether or not the company files for acceleratedapproval of eteplirsen. However, the firm believes anFDA nod for accelerated approval would be a clear positive for Sarepta. Leerink has an Outperform rating on the stock with a $45 price target.